CFT1946 is an orally active bifunctional degradation activating compound designed for selective degradation of the BRAF V600E mutant through a CRBN-based mechanism. Its structural features enable it to effectively target various BRAF mutations, including G469A, G466V, and the p61-BRAF V600E splice variant, making it valuable for investigating tumor biology.
Usually ships within 24 hours.